News & Updates

Faecal microbiota transplantation (FMT) shows no evidence of clinical benefit in the treatment of irritable bowel syndrome (IBS) in the phase III REFIT2 trial.

An association exists between polygenic risk scores (PRS) and diabetes risk, irrespective of traditional risk factors, according to a study in Japanese general populations.

A recent study has shown the feasibility of 24-week abrocitinib tapering in well-responding patients with moderate-to-severe atopic dermatitis (AD), reducing treatment burden without compromising efficacy.

Sotatercept, when added to background therapy, helps improve outcomes for children with pulmonary hypertension, as shown in a retrospective study.

Once-weekly TG103, a novel long-acting GLP-1*/Fc fusion protein, demonstrates noninferiority to dulaglutide in reducing HbA_1c in Chinese patients with type 2 diabetes (T2D) inadequately controlled on metformin, according to a phase III trial presented at EASD 2026.

Adolescents with moderate-to-severe chronic hand eczema report a considerable improvement in their quality of life following treatment with delgocitinib cream, according to data from the international phase III DELTA TEEN study.

A pharmacist monitoring programme has helped increase the use of sodium-glucose cotransporter 2 (SGLT2) inhibitors in patients with heart failure with an ejection fraction (HFEF) >40 percent, driven by improved documentation, according to a study.